Amsel Medical Achieves Major Milestone with SBIR Contract
With great excitement, Amsel Medical Corporation has been awarded a significant $7.45 million Phase III SBIR contract, aimed at the commercialization of its cutting-edge Temporary Vascular Occlusion Clamp (TVOC) technology. This innovative device is being developed to address the critical and urgent need for effective hemorrhage control, particularly benefitting those in high-stakes environments such as combat.
Understanding the Scope of the SBIR Contract
This award represents a pivotal achievement not only for Amsel Medical but also for the future of trauma care in military settings. The funding enables the company to build upon its previous successes within the Air Force’s AFWERX Phase I and II initiatives, as well as the Tactical Funding Increase (TACFI) contract initiatives. These past experiences have equipped Amsel Medical with the foundation necessary to push forward into advanced stages of development.
Accelerating Innovation for Hemorrhage Control
The focus of this contract is to speed up the commercialization process of Amsel's revolutionary SCureTO™ device. This solution is specifically designed to aid combat casualty care, providing the Department of the Air Force and the broader U.S. Department of Defense with exceptional tools for managing severe bleeding in critical situations.
SCureTO™: A Game Changer in Trauma Care
The SCureTO™ device employs a unique mechanism that allows for rapid, minimally invasive clamping of arteries directly at the injury site, ensuring effective control of hemorrhage at significant junctions. This capability is invaluable, especially in cases where standard tourniquets fail to achieve the required control. Medical responders have the ability to regulate the flow of blood from the affected area, providing them with essential time to transport patients safely without escalating complications, such as limb ischemia, that commonly occur in trauma situations.
Voices from Leadership—A Perspective on Priorities
James A. Heinz, the CEO of Amsel Medical, expressed his enthusiasm regarding the importance of this development, stating, "The challenge of managing hemorrhage effectively in the prehospital environment emphasizes the importance of our device. A successful transition from tourniquet application to a more versatile solution can ultimately save limbs and lives. Our mission is clear, and we are committed to improving urgent care in battlefield conditions and civilian settings alike."
Expert Commentary on the Health System Impact
Colonel (ret) John Dorsch, formerly the U.S. Air Force's surgeon general for the 24th Special Operations Wing, weighed in on the potential impacts of the SCureTO™ technology, noting that its ability to address junctional hemorrhages—particularly those that cannot be managed with external tourniquets—will be an essential innovation for surgical care in military operations.
About Amsel Medical Corporation
Amsel Medical Corporation stands at the forefront of medical device innovation, developing effective clamping technologies designed for both temporary and permanent occlusion of vascular structures. They are committed to providing advanced solutions, including the SCureClamp™, all aimed at enhancing performance in trauma scenarios.
Connecting with Amsel Medical
For those interested in learning more about Amsel Medical and its groundbreaking products, the official website provides extensive information on their innovations and ongoing projects. The development of SCureTO™ represents a leap forward in preventing blood loss during trauma care, highlighting Amsel’s dedication to improving medical outcomes.
Frequently Asked Questions
What is the significance of the $7.45 million SBIR contract?
The contract allows Amsel Medical to advance their SCureTO™ technology, focusing on effective hemorrhage control solutions.
How does the SCureTO™ device function?
SCureTO™ provides minimally invasive arterial clamping to control hemorrhage, especially critical in situations where traditional methods fail.
Who benefits from the use of the SCureTO™ device?
The technology is designed for use in both military and civilian trauma scenarios, aiming to save lives in urgent care situations.
What challenges does Amsel Medical aim to solve?
Amsel Medical addresses the vital need for effective hemorrhage control techniques in prehospital care environments.
Where can I find more information about Amsel Medical?
You can visit Amsel Medical's official website for comprehensive details about their innovations and mission.
